ArticleScientific reports2026
Hydronephrosis modifies the association between ureteroscopy and intravesical recurrence risk after radical nephroureterectomy for upper tract urothelial carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates whether ureteroscopy (URS) increases intravesical recurrence (IVR) risk following radical nephroureterectomy for upper tract urothelial carcinoma and identifies vulnerable patient subgroups. Previous studies did not fully clarify the impact of URS and biopsy on IVR risk, or whether the risk is elevated in specific subgroups. We retrospectively analyzed 1,483 patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma at nine institutions between January 2001 and April 2024. Cox proportional hazards models identified risk factors for IVR. Subgroup analyses determined characteristics increasing recurrence susceptibility. Inverse probability of treatment weighting validated subgroup analyses results. The median follow-up period was 45.1 (IQR 21.1–79.4) months. Multivariable analysis revealed that male sex, lower clinical T stage, concomitant bladder cancer, and pathological node-negative status were significantly associated with shorter IVR-free survival and confirmed URS as an independent risk factor for recurrence (HR = 1.30, 95% CI: 1.10–1.53, P < 0.001). URS-associated recurrence risk varied most by the presence of hydronephrosis. In weight-adjusted cohorts, IVR-free survival was significantly shorter with URS compared to non-URS among patients without hydronephrosis (HR = 1.73, 95% CI: 1.35–2.21, P < 0.001), whereas no significant differences were observed among patients with hydronephrosis (HR = 1.11, 95% CI: 0.88–1.40, P = 0.4). URS was an independent risk factor for IVR, but was not associated with increased risk among patients with hydronephrosis, whereas significantly increased risk was observed in patients without hydronephrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.